Tens of Thousands Worldwide Die of Antibiotic-Resistant Bacteria

MedicalResearch.com Interview with:
"Antibiotics" by Michael Mortensen is licensed under CC BY-SA 2.0Dr Alessandro Cassini MD

Epidemiologist, European Centre for Disease Prevention and Control
Solna, Sweden

MedicalResearch.com: What is the background for this study?

Response: We published an ECDC study estimating attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the European Union and the European Economic Area (EU/EEA). This study is based on 2015 data from the European Antimicrobial Resistance Surveillance Network (EARS-Net).

The study was developed by experts at ECDC and the Burden of AMR Collaborative Group, and published in The Lancet Infectious Diseases.

Continue reading

Resistance to Carbapenem Antibiotics Doubled in Intensive Care Units

MedicalResearch.com Interview with:

Eilish McCann, PhD</strong> Director, Outcomes Research (Center for Observational and Real-World Evidence) Merck

Dr. Eilish McCann

Eilish McCann, PhD
Director, Outcomes Research (Center for Observational and Real-World Evidence)
Merck

MedicalResearch.com: What is the background for this study?

Response: One of the most pressing challenges facing medicine today is the emergence of bacterial resistance to antibiotics. One area of high concern is the increasing prevalence of resistance to powerful antibiotics like carbapenems, as patients with infections due to carbapenem-resistant bacteria have very few alternate effective treatment options.

In this study we used real-world data from a Becton, Dickinson and Company electronic research data set to analyze over 140,000 bacterial isolates from patients at 342 hospitals across the United States, so that we could investigate where the burden of carbapenem resistance is most acute. Importantly analysis of real-world data in this way allows us to gain insights from a large number of hospitals, giving a broad and nationally representative picture of the resistance burden.

Continue reading

Travelers Often Bring Home Resistant Bacteria From Endemic Areas

MedicalResearch.com Interview with:

John Penders PhD Assistant professor Dept. of Medical Microbiology Maastricht University, Maastricht

Dr. John Penders

John Penders PhD
Assistant professor
Dept. of Medical Microbiology
Maastricht University, Maastricht

MedicalResearch.com: What is the background for this study?

Response: Antimicrobial resistance (AMR) constitutes an increasingly important human health hazard worldwide. Especially, the rapid emergence and global spread of multidrug resistant Enterobacteriaceae is worrisome. These bacteria often produce enzymes like extended-spectrum beta-lactamases (ESBLs) and carbapenemases, which inactivate most beta-lactam antibiotics, and are often co-resistant to multiple other antibiotic classes. Consequently, treatment options for infections with multidrug resistant Enterobacteriaceae are limited.

The prevalence of antimicrobial-resistant bacteria is generally higher in low and middle income countries as a result of inappropriate use of antimicrobial agents, overcrowding and lack of hygiene and infection control measures. The exponential increase of international travel to such endemic areas may substantially contribute to the emergence and spread of AMR as it allows resistant bacteria to be rapidly transported between regions.

Indeed several previous studies had already indicated that international travel is a major risk factor for colonisation with ESBL-producing Enterobacteriaceae. However, many questions remained unanswered, such as the travel destinations and potential risk-behaviour that provide the highest risk for colonisation, how long travellers remain colonised after they return and whether they can transmit these resistant bacteria to other people within their household once they returned from their travel.

That is why we initiated the largest prospective study on the acquisition and spread of multidrug resistant bacteria in returning travellers. This multicenter study, conducted by Maastricht University Medical Center, Erasmus University Medical Center, Academic Medical Center Amsterdam, Havenziekenhuis and Utrecht University, included 2,001 travellers and 215 household members. Fecal samples of these participants were collected before and immediately after travel as well as 1, 3, 6 and 12 months after travel return and screened for the prescence of multidrug resistant Enterobacteriaceae. Moreover, extensive information on demographics, travel details, illnesses and behaviour were collected at all follow-up moments by repeated questionnaires.

Continue reading

33% Rise In ‘Last-Resort’ Antibiotics Use in Hospitals

MedicalResearch.com Interview with:

James Baggs, PhD CDC

Dr. James Baggs

James Baggs, PhD
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention
Atlanta, Georgia

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: We used medical claims data to estimate the amount of antibiotics used in US hospitals from 2006 – 2012. Data came from the Truven Health MarketScan Hospital Drug Database, which included about 300 hospitals and more than 34 million discharges. Antibiotic use in hospitals was very common with more than half of patients receiving at least one antibiotic during their hospital stay. Overall rates of antibiotic use in U.S. hospitals did not change over time; however, there were significant changes in the types of antibiotics prescribed.

Importantly, the types of antibiotics with the largest increases in use were the types of antibiotics often considered to be the most powerful. Of particular concern, there was a 37% rise in the use of carbapenems, commonly referred to as “last resort” antibiotics.

Continue reading